The BioMADE machine learning framework predicted Torsades de Pointes risk with an AUROC of 0.89 in internal validation and outperformed ADMEThyst on its validation set (AUROC 0.74 vs 0.72).
The BioMADE machine learning framework provides a scalable, biology-informed approach that outperforms purely chemical or structural descriptors in predicting drug-induced Torsades de Pointes risk.
Absolute Event Rate: 0.74% vs 0.72%
Drug-induced arrhythmias, particularly Torsades de Pointes (TdP), pose a significant risk to patient safety and can sometimes have life-threatening outcomes. They remain a major concern in drug development and regulation. Machine learning (ML) has become a powerful tool for analyzing complex biological and chemical datasets, enabling researchers to identify subtle patterns that differentiate safe compounds from those likely to cause dangerous cardiac effects. However, most existing in silico approaches do not sufficiently incorporate biological elements, relying heavily on chemical and structural properties or on computationally expensive simulations. Here, we introduce BioMADE, a novel ML framework that harnesses small-molecule-protein activity profiles from publicly available datasets to predict TdP risk without requiring exhaustive mechanistic annotation. Activity data from ChEMBL were used to train individual models for each gene, which predict activity values for any given compound. A curated set of arrhythmia-relevant genes was then used to construct a latent biological embedding (BioMADE embedding) for each molecule. We validated the performance of these features in distinguishing biological elements such as ATC3 class, showing superior classification performance compared with representations such as Molformer (lacks biological information) and MACCS (limited chemical properties) (0.85 AUROC vs 0.81 and 0.73, respectively). BioMADE representations served as input to a support vector machine classifier to discriminate TdP-inducing drugs from safe compounds. BioMADE achieved an AUROC of 0.89 in internal validation, indicating strong predictive performance. Against state-of-the-art models such as ADMEThyst, BioMADE achieved an AUROC of 0.74 on ADMEThyst's validation set (vs. 0.72 for ADMEThyst). When we combined both approaches, the AUROC reached 0.77. These results demonstrate that BioMADE provides a scalable, biology-informed, and generalizable approach for predicting drug-induced toxicities. By integrating protein activity profiles into toxicology modeling, our framework highlights the critical role of human biology in adverse drug reaction prediction, an aspect often overshadowed by purely chemical or structural descriptors.
Cortina et al. (Mon,) conducted a other in Drug-induced arrhythmias (Torsades de Pointes). BioMADE (machine learning framework) vs. ADMEThyst was evaluated on Discrimination of TdP-inducing drugs from safe compounds (AUROC). The BioMADE machine learning framework predicted Torsades de Pointes risk with an AUROC of 0.89 in internal validation and outperformed ADMEThyst on its validation set (AUROC 0.74 vs 0.72).